Vote Scores
Filings read through

How funds voted at ArriVent BioPharma, Inc.

Ticker
AVBP
SEC company number
1868279
Filers reporting
72, year to 30 June 2026
Latest meeting on file
Meetings on file
2

In the year to 30 June 2026, 72 filers on Form N-PX reported votes at ArriVent BioPharma, Inc.. The votes fall in one meeting. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 140 marks to the ballot items, each with or against management. 77.9% of the marks are with management.

In the year to 30 June 2026, no say-on-pay item is on file for ArriVent BioPharma, Inc.. So there is no figure to give.

By filers reporting in the year to 30 June 2026, ArriVent BioPharma, Inc. was number 4,330 of 11,972 companies with a page and votes in that year. The number of filers reporting at ArriVent BioPharma, Inc. rose by 28.6% from the year to 30 June 2025 to the year to 30 June 2026. At the companies on this site with filers in both years, the total of filers reporting rose by 6.0%. In all seasons on file, category AUDIT-RELATED is 28.1% of the vote records at ArriVent BioPharma, Inc.. At all companies on this site, it is 6.8%.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 18 Jun 2026

72 filers reported votes at this meeting in the year to 30 June 2026. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    3 nominees. 55.3% of the reported votes are for. 62 filers withheld from or voted against at least one nominee.

    423 vote records from 72 filers. 31 of the 70 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 30 fund families
    • For 13
    • Abstain or withhold 16
    • Split or no vote 1
    • Against management 15
  2. Item 2: Audit-related items (auditor ratification)

    141 vote records from 72 filers. 0 of the 70 filers that marked the item voted against management. 2 filers gave no management mark.

    • Positions of 30 fund families
    • For 29
    • Split or no vote 1

Positions of the fund families at the meeting of 18 Jun 2026

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at ArriVent BioPharma, Inc., meeting of 18 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familyAuditor
American CenturyFor
BlackRock and iSharesFor
Brighthouse FundsFor
Charles SchwabFor
Columbia ThreadneedleFor
DimensionalFor
DWSFor
EquitableFor
FidelityFor
Global XFor
Goldman SachsFor
Guggenheim and RydexFor
InvescoFor
J.P. MorganFor
Jackson National fundsSplit
John Hancock and ManulifeFor
Lincoln FinancialFor
Morgan Stanley, Eaton Vance and CalvertFor
NationwideFor
Northern Trust and FlexSharesFor
Nuveen and TIAAFor
Pacific Life fundsFor
PrincipalFor
ProShares and ProFundsFor
SEIFor
State Street and SPDRFor
T. Rowe PriceFor
VanguardFor
Victory CapitalFor
VoyaFor

Every meeting on file

Meetings of ArriVent BioPharma, Inc., from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 2026722not reported
year to 30 June 2025562not reported

Say-on-pay, season by season

Say-on-pay at ArriVent BioPharma, Inc.: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 202672not reportednot reported
year to 30 June 202556not reportednot reported
ArriVent BioPharma, Inc. and the median of companies on this site, year to 30 June 2026
Say-on-payThis companyMedian of companies on this site
Filers against managementnot reported6.6%
Reported shares against managementnot reported2.9%

The median covers 3,799 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at ArriVent BioPharma, Inc. by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS64771.9%
AUDIT-RELATED25328.1%

The record at the SEC

Each link loaded on .

Cite this page

Vote Scores. How funds voted at ArriVent BioPharma, Inc.. https://votescores.com/company/arrivent-biopharma-inc/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of ArriVent BioPharma, Inc. are on file?
2 meetings are on file, from 18 Jun 2025 to 18 Jun 2026. 2 meetings have 20 or more reporting filers and have their own page.
Did filers report proposals from security holders at ArriVent BioPharma, Inc.?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2026. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. ArriVent BioPharma, Inc. reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list ArriVent BioPharma, Inc., grouped by company. The name is the most common spelling among filers. The ticker and the SEC company number come from the SEC company tickers file, matched on the exact name. The filers wrote the filings. Filings read through .